merged_cord-blood-storage-contamination.txt
<question_number>1</question_number>
<answer>Private cord blood banks mislead parents by emphasizing the potential of stored stem cells to treat a wide range of diseases in the future, while downplaying the low probability of their actual use and the lack of current scientific evidence supporting many of these claims.</answer>
<question_number>2</question_number>
<answer>Cord blood bank sales representatives are exempt from anti-kickback laws that apply to pharmaceutical representatives because insurance companies do not cover their product.</answer>
<question_number>3</question_number>
<answer>FDA inspectors found that CBR failed to ensure appropriate shipping conditions, leading to stem cell samples arriving at the warehouse warmer than the accepted temperature, potentially contributing to bacterial growth and contamination.</answer>
<question_number>4</question_number>
<answer>The claim that cord blood stem cells can treat over 80 conditions is misleading, as it is based on a list that includes rare diseases and treatments using various types of stem cells, not necessarily from cord blood, and lacks FDA approval for many of the listed conditions.</answer>
<question_number>5</question_number>
<answer>Anna Lazos's case illustrates the risk of cord blood contamination, a common issue with private banks, which can render the stored samples unusable for intended treatments, despite years of payment for storage.</answer>
<question_number>6</question_number>
<answer>Chrissy Teigen</answer>
<question_number>7</question_number>
<answer>CBR</answer>
<question_number>8</question_number>
<answer>CBR</answer>
<question_number>9</question_number>
<answer>CBR</answer>
<question_number>10</question_number>
<answer>ViaCord</answer>